CA2220698A1 - N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same - Google Patents

N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same

Info

Publication number
CA2220698A1
CA2220698A1 CA002220698A CA2220698A CA2220698A1 CA 2220698 A1 CA2220698 A1 CA 2220698A1 CA 002220698 A CA002220698 A CA 002220698A CA 2220698 A CA2220698 A CA 2220698A CA 2220698 A1 CA2220698 A1 CA 2220698A1
Authority
CA
Canada
Prior art keywords
carbon atoms
groups
same
group
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002220698A
Other languages
French (fr)
Other versions
CA2220698C (en
Inventor
Toshio Maeda
Masahiro Nomura
Katsuya Awano
Susumu Kinoshita
Hiroya Satoh
Koji Murakami
Masaki Tsunoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002417403A priority Critical patent/CA2417403A1/en
Priority to CA002417408A priority patent/CA2417408A1/en
Publication of CA2220698A1 publication Critical patent/CA2220698A1/en
Application granted granted Critical
Publication of CA2220698C publication Critical patent/CA2220698C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Abstract

The present invention provides novel N-benzyldioxothiazolidylbenzamide derivatives that improve the insulin resistance and have potent hypoglycemic and lipid-lowering effects and processes for preparing the same, and relates to N-benzyldioxothiazolidylbenzamide derivatives characterized by being represented by a general formula (1) <See Formula I>

[wherein R1 and R2 denote identically or differently hydrogen atoms, lower alkyl groups with carbon atoms of 1 to 4, lower alkoxy groups with carbon atoms of 1 to 3, lower haloalkyl groups with carbon atoms of 1 to 3, lower haloalkoxy groups with carbon atoms of 1 to 3, halogen atoms, hydroxyl groups, nitro groups, amino groups which may be substituted with lower alkyl group(s) with carbon atoms of 1 to 3 or hetero rings, or R1 and R2 link to form a methylenedioxy group, R3 denotes a lower alkoxy group with carbon atoms of 1 to 3, hydroxyl group or halogen atom, and dotted line indicates double bond or single bond in combination with solid line], and processes for preparing the same.
CA002220698A 1995-06-02 1996-05-30 N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same Expired - Fee Related CA2220698C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002417403A CA2417403A1 (en) 1995-06-02 1996-05-30 N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
CA002417408A CA2417408A1 (en) 1995-06-02 1996-05-30 N-benzyldioxothiazolidybenzamide derivatives and process for producing the same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP7-159781 1995-06-02
JP15978195 1995-06-02
JP8-153139 1996-05-24
JP15313996A JP3144624B2 (en) 1995-06-02 1996-05-24 N-benzyldioxothiazolidylbenzamide derivative and method for producing the same
PCT/JP1996/001459 WO1996038428A1 (en) 1995-06-02 1996-05-30 N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CA002417408A Division CA2417408A1 (en) 1995-06-02 1996-05-30 N-benzyldioxothiazolidybenzamide derivatives and process for producing the same
CA002417403A Division CA2417403A1 (en) 1995-06-02 1996-05-30 N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same

Publications (2)

Publication Number Publication Date
CA2220698A1 true CA2220698A1 (en) 1996-12-05
CA2220698C CA2220698C (en) 2003-06-17

Family

ID=26481850

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002220698A Expired - Fee Related CA2220698C (en) 1995-06-02 1996-05-30 N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same

Country Status (15)

Country Link
US (1) US6030990A (en)
EP (1) EP0846693B1 (en)
JP (1) JP3144624B2 (en)
KR (1) KR100456177B1 (en)
CN (2) CN1069901C (en)
AT (1) ATE212341T1 (en)
AU (1) AU698896B2 (en)
CA (1) CA2220698C (en)
DE (1) DE69618792T2 (en)
DK (1) DK0846693T3 (en)
ES (1) ES2170858T3 (en)
HU (1) HU225039B1 (en)
PT (1) PT846693E (en)
TW (1) TW400328B (en)
WO (1) WO1996038428A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
CZ293016B6 (en) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazole derivatives and pharmaceutical compositions in which the derivatives are comprised
AU2231397A (en) * 1996-03-08 1997-09-22 Torii Pharmaceutical Co., Ltd. Thiazolidine-2,4-dione derivatives
EE200100155A (en) 1998-09-17 2002-08-15 Bristol-Myers Squibb Company A method of treating atherosclerosis using an a2 inhibitor and a combination thereof
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
HUP0202701A3 (en) 1999-08-23 2004-12-28 Kyorin Seiyaku Kk Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
ATE296293T1 (en) * 1999-08-23 2005-06-15 Kyorin Seiyaku Kk SUBSTITUTED BENZYLTHIAZOLIDINE-2,4-DIONE DERIVATIVES
KR20020022811A (en) * 1999-08-23 2002-03-27 오기하라 이쿠오 Substituted benzylthiazolidine-2,4-dione derivatives
KR100738245B1 (en) * 1999-08-23 2007-07-12 교린 세이야꾸 가부시키 가이샤 Substituted benzylthiazolidine-2,4-dione derivatives
KR100683435B1 (en) * 1999-09-17 2007-02-20 교린 세이야꾸 가부시키 가이샤 O-Anisamide derivatives
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
TWI271192B (en) 1999-11-11 2007-01-21 Kyorin Pharmaceutical Co Ltd Solid formulation for oral administration
BR0017048A (en) * 1999-12-22 2002-11-05 Metabasis Therapeutics Inc Phosphonate bisamidate prodrugs
WO2001057007A1 (en) * 2000-02-01 2001-08-09 Kyorin Pharmaceutical Co., Ltd. Alkali metal salt of thiazolidine-2,4-dione derivative
WO2001066549A1 (en) * 2000-03-07 2001-09-13 Kyorin Pharmaceutical Co., Ltd. Intermediate compounds
CZ20023502A3 (en) * 2000-04-25 2003-06-18 Kyorin Pharmaceutical Co., Ltd. Novel stable crystalline form of thiazolidine derivative a process for preparing thereof
AU2001274502A1 (en) * 2000-06-14 2001-12-24 Kyorin Pharmaceutical Co. Ltd. Process for the preparation of thiazolidinedione derivatives
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1695716A2 (en) * 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
SI1363668T1 (en) * 2001-01-26 2007-12-31 Schering Corp Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
RS50406B (en) * 2001-01-26 2009-12-31 Schering Corporation, The use of substituted azetidinone compounds for the treatment of sitosterolemia
RS51449B (en) * 2001-01-26 2011-04-30 Schering Corporation Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
PT1353694E (en) * 2001-01-26 2008-03-12 Schering Corp Combinations of ezetimibe with aspirine for treating vascular conditions
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2434436A1 (en) * 2001-01-26 2002-08-01 Teddy Kosoglou Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
EP1671650A1 (en) * 2001-01-26 2006-06-21 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
WO2002079162A1 (en) 2001-03-28 2002-10-10 Eisai Co., Ltd. Carboxylic acids
US7244861B2 (en) 2001-03-30 2007-07-17 Eisai Co., Ltd. Benzene compound and salt thereof
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
CA2447884A1 (en) * 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
EP1394147A4 (en) 2001-06-04 2007-10-24 Eisai R&D Man Co Ltd Carboxylic acid derivative and medicine comprising salt or ester of the same
EP1452521A4 (en) 2001-08-17 2007-03-14 Eisai R&D Man Co Ltd Cyclic compound and ppar agonist
ATE345793T1 (en) * 2001-09-21 2006-12-15 Schering Corp TREATMENT OF XANTHOMA USING AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (en) 2001-11-12 2003-06-30 Pfizer Prod Inc BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS
ITRM20020016A1 (en) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti FENYL ACID DERIVATIVES (ALCHYL) CARBOXYL AND DYNIC PHENYLALKYL THEROCYCLIC DERIVATIVES, THEIR USE AS MEDICATIONS WITH HYPOGLYCEMIC ACTIVITY
WO2003088962A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
US6821524B2 (en) * 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
BR0311834A (en) 2002-06-19 2005-04-12 Lilly Co Eli Compound, pharmaceutical composition, methods for modulating a peroxisome proliferator-activated receptor, for treating and preventing diabetes mellitus in a mammal, and for treating syndrome x in a mammal, and, using a compound or pharmaceutically acceptable salt thereof.
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (en) 2002-12-31 2004-07-26 Pfizer Prod Inc BENZAMID INHIBITORS OF THE P2X7 RECEIVER.
DE10308353A1 (en) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as medicines
DE10308352A1 (en) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Branched side chain arylcycloalkyl derivatives, process for their preparation and their use as medicaments
DE10308351A1 (en) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituted cycloalkyl derivatives having acidic, usually heterocyclic groups, processes for their preparation and their use as medicaments
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (en) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl-substituted alkanoic acid derivatives, process for their preparation and their use as medicaments
US7235543B2 (en) * 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE418551T1 (en) * 2003-03-07 2009-01-15 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004005033T2 (en) * 2003-05-12 2007-08-09 Pfizer Products Inc., Groton BENZAMIDINHIBITORS OF THE P2X7 RECEPTOR
AU2004293013B2 (en) 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
JP2008504360A (en) * 2004-06-29 2008-02-14 ファイザー・プロダクツ・インク 5- [4- (2-hydroxy-propyl) -3,5-dioxo-4,5-dihydro-3H-1,2,4-triazin-2-yl by deprotecting the hydroxyl protected precursor Method for producing benzamide derivative
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
BRPI0512651A (en) * 2004-06-29 2008-03-25 Pfizer Prod Inc method for preparing 5-4- (2-hydroxyethyl) -3,5-dioxo-4,5-dihydro-3h-1,2,4-trizin-2-yl derivatives with p2x7 inhibitory activity by reaction of the derivative not substituted at position 4 of trizine with an oxirane in the presence of a lewis acid
AU2005277479A1 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
DE102005026762A1 (en) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
KR100958831B1 (en) * 2006-09-19 2010-05-24 주식회사유한양행 Heteroarylalkoxy-phenyl derivatives, processes for the preparation thereof, and compositions comprising the same
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
FR2680512B1 (en) * 1991-08-20 1995-01-20 Adir NOVEL 2,4-THIAZOLIDINEDIONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
NO302519B1 (en) * 1991-12-26 1998-03-16 Sankyo Co Thiazolidine compounds containing a quinone group, and pharmaceutical composition

Also Published As

Publication number Publication date
CN1186489A (en) 1998-07-01
CA2220698C (en) 2003-06-17
CN1336366A (en) 2002-02-20
EP0846693B1 (en) 2002-01-23
ATE212341T1 (en) 2002-02-15
HUP9802565A3 (en) 2000-01-28
DE69618792D1 (en) 2002-03-14
PT846693E (en) 2002-05-31
WO1996038428A1 (en) 1996-12-05
DK0846693T3 (en) 2002-05-06
DE69618792T2 (en) 2002-10-10
KR19990022435A (en) 1999-03-25
EP0846693A1 (en) 1998-06-10
JPH0948771A (en) 1997-02-18
ES2170858T3 (en) 2002-08-16
TW400328B (en) 2000-08-01
HUP9802565A2 (en) 1999-04-28
AU698896B2 (en) 1998-11-12
CN1069901C (en) 2001-08-22
HU225039B1 (en) 2006-05-29
CN1133627C (en) 2004-01-07
KR100456177B1 (en) 2004-12-30
US6030990A (en) 2000-02-29
JP3144624B2 (en) 2001-03-12
AU5844696A (en) 1996-12-18
EP0846693A4 (en) 1999-03-03

Similar Documents

Publication Publication Date Title
CA2220698A1 (en) N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
AU2011697A (en) N-substituted dioxothiazolidylbenzamide derivatives and the process for preparing the same
DE68906552D1 (en) CAMPTOTHECIN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
CA2105251A1 (en) Novel processes for the production of 13-ether derivatives of milbemycins, and novel intermediates therefor
AU2465195A (en) Preparation of a camptothecin derivative by intramolecular cyclisation
MXPA02012875A (en) Benzoylpyridine derivative or its salt, fungicide containing it as an active ingredient, its production process and intermediate for producing it.
AU7116691A (en) Process for the preparation of oxetanones
CA2214793A1 (en) Novel intermediates and process for the manufacture of camptothecin derivatives (cpt-11) and related compounds
AU4321397A (en) Pyrazolopyridylpyridazinone derivatives and process for preparing the same
CA2217771A1 (en) O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same
AU3274997A (en) Intermediates for the preparation of duocarmycin sa and derivatives thereof, and process for the production of the intermediates
CA2221946A1 (en) Production process of cyclic compound
EP1157739A4 (en) Catalyst for producing acetic acid, method for preparing the same and method for producing acetic acid using the same
CA2195975A1 (en) An improved process for preparing side chain derivatives of cyclohexapeptidyl lipopeptides
AU655869B2 (en) An amphoteric tricyclic compound
ZA200005110B (en) Process for preparing intermediates.
EG20562A (en) Process for preparing glutaramide derivatives
AU1683500A (en) Hydronaphtho(2,3-C)furan derivatives and process for the preparation thereof
AU7206898A (en) Method for producing 1,3-di-substituted 2-nitroguanidines
CA2223772A1 (en) Process for the preparation of 3,4-dihydroxy-3-cyclobutene-1,2-dione
CA2348374A1 (en) Method for producing 4- [(2&#39;,5&#39;- diamino-6&#39;- halopyrimidine- 4&#39;-yl)amino]- cyclopent- 2-enylmethanols
EP0882713A4 (en) Process for preparing halogenopyridine derivatives
EP0807617A4 (en) Process for preparing 1,5-pentanediol derivative
WO2002008248A1 (en) Method for producing peptide derivative
CA2172946A1 (en) N-(.alpha.-alkylbenzylidene)-.alpha.-phenylalkylamine, its use and process for producing the same and process for producing intermediate

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed